Exhalation Technology Announces Plans for Commercial Launch and Clinical Update on CoronaCheck
Exhalation Technology Announces Plans for Commercial Launch and Clinical Update on CoronaCheck – A Rapid (<5 minutes) Covid-19 Diagnostic Test for Exhaled Breath
Cambridge, England, 6 April 2021 – Exhalation Technology (ETL), a Cambridge, UK-based company, announced updated results from its clinical study on humans with its novel, rapid (<5 minutes) CoronaCheck Point-of-Care diagnostic test for Covid-19 in exhaled breath condensate (EBC). ETL believes the CoronaCheck test will be the fastest and simplest Covid-19 test when it receives approval and achieves commercial launch.
ETL announced that its CoronaCheck test will be CE marked in Europe by early May 2021 and also that it has applied to the US FDA for Emergency Use Authorisation (EUA). It hopes to gain this approval no later than end May 2021.
ETL has also announced that it has published an Instruction for Use video for the general public on YouTube at https://www.youtube.com/watch?v=X_WsyBV7Csw. This video shows the simplicity of the CoronaCheck testing approach.
ETL have developed CoronaCheck, a rapid test specific for Covid-19 virus, exploiting their expertise in exhaled breath diagnostics. ETL has announced that is has now tested 134 patients to date, and CoronaCheck has detected with 99% specificity and 95% sensitivity those patients who are either positive or negative for Covid-19.
Within the Healthy Control cohort, CoronaCheck also detected Covid-19 in 14 asymptomatic humans in a blinded test which, like all of their trial results, was confirmed by “gold standard” rtPCR also to be positive. CoronaCheck also found 1 symptomatic patient who tested negative with CoronaCheck and was confirmed negative by rtPCR.
CoronaCheck uses electrochemical sensor detection for Covid-19 similar to that which has been employed for glucose testing in diabetic patients for more than 40 years, and is capable of mass production with an IP-protected approach. ETL have also announced that CoronaCheck is detecting all variants of the original Covid-19 virus which it has been able to test to date. However, CoronaCheck does not detect any of the common respiratory viruses or bacteria associated with colds and seasonal flu.
CoronaCheck is able to detect as few as 12 copies of virus on the sensor; infected patients are expected to exhale as much as 150 copies in the volumes being tested by CoronaCheck.
CoronaCheck is a rapid test (aims for a result in under 5 minutes) of high specificity and sensitivity for Covid-19, meeting the need for efficient and accurate testing in a wide range of environments including hospitals, care homes, airports, retail outlets, schools and similar spaces.
CoronaCheck has been developed in collaboration a leading virology laboratory in the UK and with Zimmer Peacock, a developer of electrochemical sensor technology based in the UK and Norway.
The ETL clinical trial program for CoronaCheck at the Clinic for Respiratory Medicine based in The Queen Alexandra Hospital, Portsmouth, is headed by professor Anoop Chauhan. This has enabled a cohort of up to 150 patients to be tested in an ethics-approved clinical trial on infected and normal patients.
ETL have also announced it will initiate in April 2021 a large clinical study in Denmark comprising 400 symptomatic and 400 asymptomatic patients.
ETL is in discussion with several global strategic partners with which it can collaborate to exploit its new Covid-19 test.
ETL has developed CoronaCheck, a very unique and timely, IP-protected test for rapid detection of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2 also known as Covid-19), using a novel biosensor housed in a safe breath analysis device suitable for rapid point-of-care coronavirus testing. The test measures directly the presence of virus in breath, as opposed to antibodies in the blood.
CoronaCheck has safety features to prevent cross-infection and contamination, to measure the SARS-CoV-2 virus in exhaled breath.
Helle Funch Nielsen, CEO of ETL, said “Initial results from patients recruited into our clinical study at Portsmouth are highly impressive and encouraging, due to the very simple composition of exhaled breath condensate compared to other test environments such as blood, urine and saliva. The novel Covid-19 sensor we have developed with our partners Zimmer Peacock is proving highly sensitive and specific, able to deliver very reliable results in a matter of minutes and accurately detecting all known variants of the virus which we have been able to source.”
Stig Lytke Brejl, Director of ETL, said “The successful trial of CoronaCheck has encouraged us to initiate a scaleup process which can take us eventually to 5 million tests per month, potentially more. Our partner discussions are encouraging in our search for one or more corporate entities who can work with us to scale up the technology and get the tests into the hands of a number of environments where reliable and rapid test results are badly needed..”
CoronaCheck does not require any laboratory equipment or special handling or training, and is likely to be CLIA-waived by FDA. The biosensor is mounted in a test cartridge which is inserted into the device into which the subject breathes with results obtained in minutes, whereupon the test cartridge is safely discarded and the device is ready for a new test cartridge and subject.
For more information about Exhalation Technology and partnering opportunities for its Covid-19 test, please contact:
Dr. Bill Mason The Sage Group The Old Black Barns Lord’s Lane, Ousden CB8 8TX UK Tel: +44 (0) 7785 950134 email@example.com
Wayne Pambianchi The Sage Group Inc. 1802 Route 31 North #381 Clinton New Jersey 08809 USA Phone: +1 908 2306170 firstname.lastname@example.org
Helle Funch Nielsen Tel: +45 2830 7858 email@example.com
About Exhalation Technology
Exhalation Technology develops breath analysis devices for disease diagnosis, monitoring, and management.
ETL aims to revolutionise respiratory care by providing clinicians the tools they need to provide optimal patient care – with confidence.
By giving clinicians access to information related to underlying causes, ETL can strengthen their decision-making process – and create better outcomes for patients.
Why? Because ETL believe monitoring and managing respiratory diseases should be simple and reliable – for everyone involved. ETL is committed to helping transform the way we diagnose, treat and monitor respiratory diseases.
In improving patient outcomes, we help clinicians meet the challenges and opportunities in an ever-evolving respiratory healthcare world.
About The Sage Group, Inc.
The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million.
The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.
The range of services offered includes:
Strategic alliances and licensing/partnering
M&A, divestment, buy- and sell- side
Global product and technology acquisition searches
Strategic assessment and planning
Due diligence, technology and molecule assessment, valuation
New ventures, interim management
Facilitating investment in R&D and/or company equity through introductions, network and brokering
The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals have also held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist industry participants in these challenging times.